Loading...
XNASAZTA
Market cap2.36bUSD
Jan 10, Last price  
51.70USD
1D
-0.21%
1Q
14.15%
Jan 2017
202.87%
Name

Azenta Inc

Chart & Performance

D1W1MN
XNAS:AZTA chart
P/E
—
P/S
3.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-5.98%
Rev. gr., 5y
-3.44%
Revenues
656m
-1.32%
463,746,000692,870,000743,258,000526,366,000218,706,000592,972,000688,105,000519,451,000450,952,000482,848,000552,708,000560,323,000692,885,000631,560,000781,865,000897,273,000513,703,000555,498,000665,072,000656,323,000
Net income
-164m
L+1,051.50%
-10,057,00025,930,000151,472,000-235,946,000-227,858,00058,982,000128,352,000136,789,000-2,215,00031,361,00014,221,000-69,476,00062,612,000116,575,0009,890,00064,853,000-28,869,000-11,286,000-14,257,000-164,170,000
CFO
50m
+187.53%
31,114,00065,192,00072,873,00013,656,000-56,494,00027,872,00087,650,00036,038,00054,389,00053,781,00043,727,00039,547,00096,224,00073,964,00090,898,00037,866,000149,857,000-466,046,00017,490,00050,289,000
Dividend
Dec 02, 20210.1 USD/sh
Earnings
Feb 05, 2025

Profile

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
URL
https://www.azenta.com/
IPO date
Feb 02, 1995
Employees
4,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
656,323
-1.32%
665,072
19.73%
555,498
8.14%
Cost of revenue
426,481
435,888
327,456
Unusual Expense (Income)
NOPBT
229,842
229,184
228,042
NOPBT Margin
35.02%
34.46%
41.05%
Operating Taxes
(3,153)
(17,550)
1,350
Tax Rate
0.59%
NOPAT
232,995
246,734
226,692
Net income
(164,170)
1,051.50%
(14,257)
26.32%
(11,286)
-60.91%
Dividends
(7,494)
Dividend yield
0.23%
Proceeds from repurchase of equity
(658,424)
(838,514)
5,245
BB yield
25.56%
25.22%
-0.16%
Debt
Debt current
7,020
Long-term debt
118,922
120,872
98,454
Deferred revenue
Other long-term liabilities
11,530
79,856
6,724
Net debt
(343,169)
(1,008,249)
(1,816,584)
Cash flow
Cash from operating activities
50,289
17,490
(466,046)
CAPEX
(37,392)
(39,436)
(77,435)
Cash from investing activities
224,739
431,384
1,465,590
Cash from financing activities
(659,207)
(844,080)
(62,762)
FCF
190,561
663,620
(110,007)
Balance
Cash
462,091
1,017,783
1,570,038
Long term investments
111,338
352,020
Excess cash
429,275
1,095,867
1,894,283
Stockholders' equity
1,463,965
1,579,296
1,572,325
Invested Capital
1,411,352
1,578,925
1,825,613
ROIC
15.58%
14.49%
11.70%
ROCE
12.13%
8.57%
6.58%
EV
Common stock shares outstanding
53,175
66,253
74,897
Price
48.44
-3.49%
50.19
17.10%
42.86
-58.12%
Market cap
2,575,797
-22.54%
3,325,238
3.59%
3,210,085
-57.88%
EV
2,232,628
2,316,989
1,393,501
EBITDA
320,586
314,768
281,744
EV/EBITDA
6.96
7.36
4.95
Interest
4,589
Interest/NOPBT
2.01%